Summary of retrospective studies describing the prevalence of RS in patients with CLL
| Reference . | Study period . | Cohort restricted to newly diagnosed CLL patients . | No. of CLL patients . | No. of patients with biopsy-proven RS . | Median follow up of CLL, years . | Prevalence of RS (%) . | Median time to development of RS, years (range) . |
|---|---|---|---|---|---|---|---|
| 4 | 1984-1994 | No | 1011 | 18 | NR | 1 | NR |
| 7 | 1975-2005 | No | 3986 | 148 | NR | 3.7 | NR |
| 20 | 1996-2006 | No | 185 | 17 | 4 | 9.1 | 1.9 (0-6.8) |
| 18 | 1969-2007 | No | 465 | 24 | NR | 5 | 5 (0.1-21) |
| 21 | NR | No | 783 | 69 | 3.5 | 8.8 | 1.9 (NR) |
| 19 | 2004-2010 | No | 149 | 16 | 3.5 | 10.7 | 2.7 (0-6.5) |
| 2 | 2000-2011 | Yes | 1641 | 37 | 4 | 2.1 | 1.8 (0-11.7) |
| Reference . | Study period . | Cohort restricted to newly diagnosed CLL patients . | No. of CLL patients . | No. of patients with biopsy-proven RS . | Median follow up of CLL, years . | Prevalence of RS (%) . | Median time to development of RS, years (range) . |
|---|---|---|---|---|---|---|---|
| 4 | 1984-1994 | No | 1011 | 18 | NR | 1 | NR |
| 7 | 1975-2005 | No | 3986 | 148 | NR | 3.7 | NR |
| 20 | 1996-2006 | No | 185 | 17 | 4 | 9.1 | 1.9 (0-6.8) |
| 18 | 1969-2007 | No | 465 | 24 | NR | 5 | 5 (0.1-21) |
| 21 | NR | No | 783 | 69 | 3.5 | 8.8 | 1.9 (NR) |
| 19 | 2004-2010 | No | 149 | 16 | 3.5 | 10.7 | 2.7 (0-6.5) |
| 2 | 2000-2011 | Yes | 1641 | 37 | 4 | 2.1 | 1.8 (0-11.7) |
NR, not reported.